2025
The implementation of artificial intelligence in serial monitoring of post gamma knife vestibular schwannomas: A pilot study
Singh M, Jester N, Lorr S, Briano A, Schwartz N, Mahajan A, Chiang V, Tommasini S, Wiznia D, Buono F. The implementation of artificial intelligence in serial monitoring of post gamma knife vestibular schwannomas: A pilot study. Clinical Imaging 2025, 123: 110495. PMID: 40388858, DOI: 10.1016/j.clinimag.2025.110495.Peer-Reviewed Original ResearchConceptsGamma knife radiosurgeryVestibular schwannomaPost-GKSTumor growthVS volumeHalting tumor growthRetrospective cohort studyAssess treatment efficacyManual segmentationHearing lossBenign tumorsPaired t-testT1-weighted MRI scansAssess statistical significanceCohort studyDice similarity coefficientNeurological functionTreatment efficacyClinical monitoringMRI scansStatistical significancePercentage changeSchwannomaSpatial overlapTumorPrecision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias O, Mandell J, Anderson K, Townsend J. Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 2025, 202: 108487. PMID: 40090261, DOI: 10.1016/j.lungcan.2025.108487.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsCell lung cancerLung cancer patientsEvolution of drug resistanceLung cancerDrug resistanceCancer patientsTyrosine kinase inhibitor therapyKinase inhibitor therapyTyrosine kinase inhibitorsPersonalized therapeutic strategiesTKI therapyInhibitor therapyTherapeutic failureResistance mutationsTherapeutic efficacyKinase inhibitorsAPOBEC mutationsTherapeutic strategiesTreatment efficacyCancer progressionImprove outcomesCancerHarnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, Tan D, Tan W, Ang H, Carbone D, Yee M, Shanmugam M, Huang X, Sethi G, Tan T, Lim L, Huang R, Ungefroren H, Giovannetti E, Tang D, Bruno T, Luo P, Andersen M, Qian B, Ishihara J, Radisky D, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper K, Shi T, Merghoub T, Krebs S, Kusumbe A, Davids M, Brown J, Kumar A. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. Journal Of Hematology & Oncology 2025, 18: 6. PMID: 39806516, PMCID: PMC11733683, DOI: 10.1186/s13045-024-01634-6.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTumor microenvironmentCancer progressionTherapeutic resistanceCancer therapyTumor microenvironment componentsTumor microenvironment modulationModulation of epithelial-mesenchymal transitionPromote tumor growthImprove treatment efficacyTumor microenvironment signalsTargeted cancer therapyTarget various componentsTherapeutic challengeTreatment responseTumor growthPromote metastasisTherapeutic strategiesTreatment efficacyEpithelial cellsMesenchymal traitsCancer cellsExtracellular matrix componentsCancerResistance mechanismsHIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature
Vageli D, Doukas P, Georgiou D, Prokopiou M, Ladaki N, Papadopoulou A, Doukas S, Zacharouli K, Makaritsis K, Ioannou M. HIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature. Frontiers In Bioscience-Landmark 2025, 30: 27004. PMID: 39862086, DOI: 10.31083/fbl27004.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorTreatment efficacyHIF-1aUpregulation of pro-inflammatory moleculesPotential biomarkersMitogen-activated protein kinaseAttenuation of atherosclerosis progressionOverexpression of vascular endothelial growth factorVascular endothelial growth factor protein expressionIncreased VEGFVascular endothelial growth factor overexpressionLipopolysaccharide-induced tumor necrosis factor-alpha factorAtherosclerosis progressionSystematic reviewTumor necrosis factor-alphaVascular smooth muscle cellsExposure to methamphetamineAdenosine receptor antagonistHypoxia-inducible factor-1 alphaNecrosis factor-alphaNitric oxideChronic exposure to methamphetamineEndothelial growth factorSmooth muscle cellsEvaluation of treatment efficacyCHAPTER 18 Remote monitoring of sleep apnea patients
Kongpakpaisarn K, Thapa S, Won C. CHAPTER 18 Remote monitoring of sleep apnea patients. 2025, 169-192. DOI: 10.1016/b978-0-323-87041-2.00027-0.Peer-Reviewed Original ResearchCHAPTER 15 Telehealth CBT-I
Schneeberg L, Rubman S. CHAPTER 15 Telehealth CBT-I. 2025, 135-146. DOI: 10.1016/b978-0-323-87041-2.00024-5.Peer-Reviewed Original ResearchCBT-ICBT-I.Telehealth cognitive behavioral therapyCognitive behavioral therapyTherapeutic allianceBehavioral therapyInsomnia treatmentTreatment componentsSleep difficultiesCollect sleep dataInsomniaSleep dataAvailability of providersDiscussion of legislationReview definitionsTreatment efficacySleepTelehealthCOVID-19 pandemicAlliance
2024
Bioimaging of Neuroimmune Disorders: Physical Principles of Neuroimaging Modalities and Clinical Applications
Mayeli M, Ernst T, Chang L. Bioimaging of Neuroimmune Disorders: Physical Principles of Neuroimaging Modalities and Clinical Applications. 2024, 807-830. DOI: 10.1007/978-3-031-68237-7_45.Peer-Reviewed Original ResearchMagnetic resonance imagingPositron emission tomographyPsychiatric disordersSubstance use disordersAssess treatment efficacyMonitoring disease progressionChronic painMechanisms of diseaseDisease progressionTreatment efficacyViral infectionNeuroimmune aspectsNeuroimaging techniquesEmission tomographyResonance imagingNeuroimaging findingsClinical applicationNeuroimaging modalitiesModalitiesDisordersImaging techniquesDiseaseRace and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Hortobagyi G, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal Of The National Cancer Institute 2024, 117: 889-897. PMID: 39656951, PMCID: PMC12058262, DOI: 10.1093/jnci/djae314.Peer-Reviewed Original ResearchInvasive disease-free survivalHormone receptor-positiveRecurrence scoreRxPONDER trialClinical outcomesReceptor-positiveBreast cancerHER2-negative breast cancerNode-positive breast cancerDisease-free survivalMultivariate Cox modelBreast cancer outcomesBody mass indexHER2-negativePositive nodesTumor sizeSurvival outcomesClinicopathological characteristicsClinical characteristicsMass indexSelf-reported race/ethnicityCancer outcomesSecondary outcomesNHB womenTreatment efficacyWeekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab. Blood 2024, 144: 7004-7004. DOI: 10.1182/blood-2024-199190.Peer-Reviewed Original ResearchTwice-weekly bortezomibTwice-weekly groupTwice-weekly dosingWeekly bortezomibMultiple myelomaPeripheral neuropathyBortezomib doseTwice-weeklyFrontline treatmentRate of PNDay 1Rates of peripheral neuropathyMedian follow-up timeTreatment efficacyBortezomib-induced peripheral neuropathyResponse rateWeeks groupBortezomib dose reductionBortezomib-containing regimensBortezomib-induced PNDose of bortezomibDiagnosis of MMIncidence of PNSingle-center studyFollow-up timeFOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H. FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types. Molecular Therapy Oncology 2024, 32: 200895. PMID: 39583007, PMCID: PMC11584611, DOI: 10.1016/j.omton.2024.200895.Peer-Reviewed Original ResearchImmunotherapy resistanceB cellsPoor response to immunotherapyExpression of Blimp-1Cancer typesResponse to immunotherapyDifferentiation of B cellsB cell subpopulationsAssociated with poor response to immunotherapyPredicting treatment responseAffecting treatment efficacyDiverse cancer typesImmunotherapy efficacyImmunotherapy patientsTumor microenvironmentTreatment responsePlasma cellsImmunotherapyImmunosuppressive effectsBlimp-1Spatial transcriptomic analysisTreatment efficacyOvercome resistanceCancer treatmentImmunofluorescence analysisInvestigating the association between the GAP-43 concentration with diffusion tensor imaging indices in Alzheimer’s dementia continuum
Ariaei A, Ghorbani A, Habibzadeh E, Moghaddam N, Chegeni Nezhad N, Abdoli A, Mazinanian S, Sadeghi M, Mayeli M. Investigating the association between the GAP-43 concentration with diffusion tensor imaging indices in Alzheimer’s dementia continuum. BMC Neurology 2024, 24: 397. PMID: 39420261, PMCID: PMC11484424, DOI: 10.1186/s12883-024-03904-9.Peer-Reviewed Original ResearchConceptsDiffusion tensor imaging valuesDiffusion tensor imagingLevels of GAP-43Cerebrospinal fluidGAP-43 levelsGAP-43MethodsA total numberMonitoring treatment efficacySuperior fronto-occipital fasciculusGrowth-associated protein 43Diffusion tensor imaging indicesSuperior corona radiateCerebrospinal fluid levelsDementia continuumFronto-occipital fasciculusFollow-upWhite matter microstructural changesTreatment efficacyCorona radiateThe influence of ovarian hormones on the putative mechanisms that promote female nicotine use
Giner P, Ortegon S, Bagdas D, O'Dell L. The influence of ovarian hormones on the putative mechanisms that promote female nicotine use. Current Opinion In Neurobiology 2024, 88: 102900. PMID: 39153250, PMCID: PMC11560049, DOI: 10.1016/j.conb.2024.102900.Peer-Reviewed Original ResearchNicotine useWithdrawal severityOvarian hormonesImpact of ovarian hormonesNicotine withdrawal severityHormonal interventionsInfluence of ovarian hormonesNovel treatment avenuesHormone-based contraceptivesWithdrawal symptomsPleasurable effectsQuit dateCessation treatmentMenstrual cyclePost-menopausalHormonal fluctuationsTreatment efficacyTreatment avenuesNicotineCessation interventionsCessation strategiesCessation approachesWithdrawalHormoneWomenClindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.
Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.Peer-Reviewed Original ResearchAcne vulgarisTreatment of acne vulgarisApplication of clindamycinCutaneous bacterial infectionsAntibiotic treatment efficacyTopical clindamycinTopical agentsOral treatmentClindamycinSystemic agentsMultiple disease statesPharmacokinetic profileTreatment efficacyAntibiotic resistanceBacterial infectionsAntibiotic mechanismsTherapeutic valueRelevance to cliniciansDisease statesDermatologyLincosamide antibioticsAnti-inflammatoryGram-positiveAnaerobic bacteriaAcneGuided internet-based LGBTQ-affirmative cognitive-behavioral therapy: A randomized controlled trial among sexual minority men in China
Yi M, Li X, Chiaramonte D, Sun S, Pan S, Soulliard Z, Eisenstadt B, Ljótsson B, Hagaman A, Pachankis J. Guided internet-based LGBTQ-affirmative cognitive-behavioral therapy: A randomized controlled trial among sexual minority men in China. Behaviour Research And Therapy 2024, 181: 104605. PMID: 39029333, PMCID: PMC11371497, DOI: 10.1016/j.brat.2024.104605.Peer-Reviewed Original ResearchInternet-based CBTCognitive-behavioral therapySexual minority menSocial-cognitive mechanismsYoung sexual minority menMinority stressMinority menSession completionBehavioral healthSexual minority individualsModeration analysisAlcohol useMinority individualsMental healthInternalized stigmaFollow-upStigma experiencesRandomized Controlled TrialsSessionsTreatment efficacySecondary outcomesControlled TrialsPrimary outcomeAffirmative supportHealthO-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results
Pellicer A, Taylor H, Alberich-Bayaari Á, Liu Y, Gamborg M, Barletta K, Heiser P, Pinton P, Bagger Y. O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results. Human Reproduction 2024, 39: deae108.021. DOI: 10.1093/humrep/deae108.021.Peer-Reviewed Original ResearchDeep infiltrating endometriosisMagnetic resonance imagingVaginal ringLesion regressionImaging biomarkersLesion sizeAdverse eventsFractional volume of extravascular extracellular spaceAssociated with chronic pelvic painPlacebo-controlled phase 2 trialAdvanced stages of endometriosisVolume of extravascular extracellular spaceDopamine D2 receptor agonistLesion burdenTreatment efficacyGroup compared to placeboSeverity of adverse eventsDIE groupPlacebo vaginal ringChronic pelvic painD2 receptor agonistLesion typePhase 2 trialStages of endometriosisCompared to placeboA Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD
Palmisano A, Meshberg-Cohen S, Petrakis I, Sofuoglu M. A Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD. Psychological Trauma Theory Research Practice And Policy 2024, 16: 768-783. PMID: 36595460, DOI: 10.1037/tra0001410.Peer-Reviewed Original ResearchPosttraumatic stress disorderBehavioral treatment outcomesEvidence-based treatmentsCognitive controlThreat processingBody of researchPTSD outcomesPTSD treatmentPaucity of researchStress disorderPreliminary supportIntermediate phenotypesTreatment dropoutMethodological limitationsStudy limitationsTreatment effectsCurrent researchTreatment approachesStrong conclusionsNovel treatment approachesEmpirical studyTreatment outcomesTreatment efficacyResearchMemoryREDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors
Yang C, Kwiatkowski E, Lee J, Lin R. REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors. Statistics In Medicine 2024, 43: 3484-3502. PMID: 38857904, PMCID: PMC11789924, DOI: 10.1002/sim.10107.Peer-Reviewed Original ResearchConceptsOptimal biological doseDose-efficacy curveDose efficacyPhase I/II trialMeta-analysisOncology trialsSpike-and-slabMultiple phase IDose-toxicity relationshipPrecision cancer treatmentEarly-phase oncology trialsOncological therapyBiological doseEfficacy dataSpike-and-slab priorsTreatment efficacyCancer treatmentExtensive simulation studyTrialsEfficacyBayesian model selection frameworkTreatmentPhase IDoseGamma processPhage Therapy for Respiratory Infections: Opportunities and Challenges
Khosravi A, Chen Q, Echterhof A, Koff J, Bollyky P. Phage Therapy for Respiratory Infections: Opportunities and Challenges. Lung 2024, 202: 223-232. PMID: 38772946, PMCID: PMC11570333, DOI: 10.1007/s00408-024-00700-7.Peer-Reviewed Original ResearchChronic lung infectionLung infectionRespiratory infectionsAntimicrobial resistancePhage therapyClinical trialsPhage therapy clinical trialsProgressive respiratory failureChronic respiratory infectionsPersonalized phage therapyAntimicrobial resistant infectionsPost-antibiotic eraPotential of phagesSalvage therapyAdjuvant therapyRespiratory failureDisease resolutionChronic respiratory diseasesTreatment efficacyTherapyTherapeutic potentialIncreased MortalityInfectionNovel antibioticsPhageEarly Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
Jacobsen L, Cuthbertson D, Bundy B, Atkinson M, Moore W, Haller M, Russell W, Gitelman S, Herold K, Redondo M, Sims E, Wherrett D, Moran A, Pugliese A, Gottlieb P, Sosenko J, Ismail H. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care 2024, 47: 1048-1055. PMID: 38621411, PMCID: PMC11294635, DOI: 10.2337/dc24-0171.Peer-Reviewed Original ResearchConceptsC-peptide area-under-the-curveArea under the curveC-peptideRecent-onset type 1 diabetesTreatment efficacyEarly-phase clinical trialsC-peptide preservationPrimary end pointB cell functionDetect treatment efficacyType 1 diabetesPost Hoc AnalysisRandomized Controlled TrialsImmune therapyImmunotherapy trialsMonths posttherapyClinical trialsTreatment effectsEnd pointsMetabolic indicesHoc AnalysisControlled TrialsType 1 diabetes trialsMetabolic endpointsIntervention trialsComparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial
Ramakrishnan D, Brüningk S, von Reppert M, Memon F, Maleki N, Aneja S, Kazerooni A, Nabavizadeh A, Lin M, Bousabarah K, Molinaro A, Nicolaides T, Prados M, Mueller S, Aboian M. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. American Journal Of Neuroradiology 2024, 45: 475-482. PMID: 38453411, PMCID: PMC11288571, DOI: 10.3174/ajnr.a8189.Peer-Reviewed Original ResearchArea under the curvePediatric gliomasBT-RADSResponse assessmentPartial responseClinical trialsVolumetric analysisReceiver operating characteristic analysisBrain Tumor ReportingReceiver operating characteristic curveModel estimation timeOperating characteristic analysisEvaluate treatment efficacyStable diseasePartial respondersManual volumetric segmentationNo significant differenceSolid tumorsProspective studyTumor ReportingClinical decision-makingTreatment efficacyGliomaSignificant differenceCharacteristic curve
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply